|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||188.61 - 192.73|
|52 Week Range||115.03 - 193.00|
|PE Ratio (TTM)||22.09|
|Forward Dividend & Yield||0.04 (0.02%)|
|1y Target Est||N/A|
Kansas and Missouri won’t see immediate rate increases after President Donald Trump ended subsidies for individual plans on the Affordable Care Act exchanges, but it’s unclear how the changes will affect insurance companies — and patients — in the long term. On Thursday, Trump confirmed that he would end cost-sharing reductions (CSRs), which delivered $7 billion to reduce out-of-pocket limits and deductibles for beneficiaries below 250 percent of the federal poverty level. The news caused a small dip in insurance companies’ stock, such as St. Louis-based Centene Corp., which closed at $93.81 on Thursday and opened at $87.06 on Friday.
Trump's announcement of his plan to eliminate cost-sharing subsidies to insurance companies sent some health care stocks lower. Here's how to trade five of them now.
The Trump White House has issued two Obamacare-related policy announcements this week: announcements that some characterize as “gutting” or “sabotaging” the health care law. But a sober, factual analysis reveals that the Trump decisions will be fairly modest—and largely positive—in their effect.
Markel's (MKL) introduction of biomedical and life sciences coverage in the US primary insurance segment supports its strategic plan to grow organically.
W.R. Berkley's (WRB) exposure to cat losses, declining gross premiums trend as well as a continued weak performance at the global reinsurance segment raise concerns.
Despite the continuing chaos and insecurity storming the health care space with respect to repeal and replace of the old order, these healthcare stocks look solid bets to put money on.
If Cigna's foray into abuse-deterrent opioids is a success, other payors may follow suit. On Wednesday, Cigna Corp. (CI) announced it would no longer cover OxyContin, the opioid painkiller manufactured by Purdue Pharma LP, starting in January. Instead, Cigna will offer Xtampza ER through a "value-based contract" with Collegium Pharmaceutical Inc.
Cigna Corp. said that, as part of an opioid-reduction plan, the company will no longer cover opioid OxyContin as a preferred option for group commercial drug lists starting next year. OxyContin is manufactured ...
Hospitals are bracing for an increase in uncompensated care after the Republican-led Congress let funding for the Children’s Health Insurance program lapse.
Amid a growing U.S. opioid addiction, health insurer Cigna Corp will stop covering OxyContin, the opioid painkiller sold by Purdue Pharma LP, as of Jan. 1 and will instead cover an equivalent with a formulation less vulnerable to abuse, the company said on Wednesday. The insurer has signed a "value-based contract" with Collegium Pharmaceutical Inc for Xtampza ER, an extended-release oxycodone equivalent that cannot be made more fast-acting through cutting or crushing. Under the contract, Collegium will reduce the cost of the medication for many of Cigna's benefit plans.
Ipsita Smolinski, managing director and health care analyst at Capitol Street, discusses President Trump's comments on health insurers and CSR payments and the impact on insurers' stocks.
Two Senators strike a major deal on crucial health care subsidies. Republican Senator Lamar Alexander and Democratic Senator Patty Murray reached an agreement to extend cost-sharing subsidies to insurance companies. In exchange, some of the law’s requirements will be dropped. The president liked the deal at first but is now backing away from it. Yahoo Finance’s Alexis Christoforous and Jen Rogers figure out why the president isn’t happy with the progress.
Senators are working on critical parts of the Affordable Care Act. Meanwhile, Senate Majority Leader Mitch McConnell prepares to meet with President Trump. Yahoo Finance's Alexis Christoforous, Myles Udland and Melody Hahm figure out exactly what is happening on Capitol Hill.
Dr. Andrew Kolodny, co-director of opioid policy research at Brandeis University’s Heller School for Social Policy, and Dr. Salim Hayek, University Hospitals pain medicine professor, discuss Cigna offering a new opioid in place of OxyCotin.
Cancer patients and people in hospice who already have OxyContin prescriptions will continue to have the drug covered in 2018, Cigna said.